Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | CNR1 | P21554 | 1/20 | 0.61 |
| ▸ | CNR2 | P34972 | 1/20 | 0.61 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.56 |
| ▸ | PRKCA | P17252 | 2/20 | 0.54 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.54 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.54 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.54 |
| ▸ | DGKA | P23743 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4451845 | 0.91 | PRKCA (0.56) | FAAHALDH1A1MAPTHPGDCNR1 | |
| SCHEMBL4458170 | 0.91 | PRKCA (0.56) | FAAHALDH1A1MAPTHPGDCNR1 | |
| SCHEMBL16612104 | 0.87 | PRKCA (0.68) | FAAHALDH1A1MAPTHPGDCNR1 | |
| SCHEMBL20985468 | 0.87 | ALDH1A1 (0.53) | FAAHALDH1A1MAPTHPGDCNR1 | |
| SCHEMBL3921806 | 0.86 | FAAH (0.65) | FAAHALDH1A1MAPTHPGDCNR1 | |
| SCHEMBL23923637 | 0.85 | PRKCA (0.50) | FAAHALDH1A1MAPTHPGDCNR1 | |
| SCHEMBL25583033 | 0.83 | FAAH (0.61) | FAAHALDH1A1MAPTHPGDCNR1 | |
| SCHEMBL26613661 | 0.83 | LMNA (0.59) | ALDH1A1MAPTPRKCAPRKCEPRKCQ | |
| SCHEMBL15668671 | 0.82 | PRKCA (0.47) | FAAHALDH1A1MAPTHPGDCNR1 | |
| SCHEMBL10417156 | 0.82 | PRKCA (0.61) | FAAHALDH1A1MAPTHPGDCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10780174-B2 | Lipid-linked prodrugs | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-09-22 | — | — | US | disclosed |
| US-20190151458-A1 | Lipid-Linked Prodrugs | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10780174-B2 | Lipid-linked prodrugs | SGMS2, SGMS1, LIPA | FAAH 72/4885ALDH1A1 728/4885MAPT 2983/4885 |
| US-20190151458-A1 | Lipid-Linked Prodrugs | SGMS2, SGMS1, LIPA | FAAH 72/4885ALDH1A1 728/4885MAPT 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.